Highest-materiality recent filing
NMS terminates license agreement with Cardiff Oncology; Cardiff disputes termination
NMS sent termination notice on May 27, 2026, citing alleged material breaches of the 2017 License Agreement.
Cardiff Oncology sues Nerviano Medical Sciences over onvansertib license inventorship dispute
Filed suit in SD California for injunctive relief and declaratory judgment it did not breach license agreement for onvansertib.
Cardiff Oncology reports Q1 cash $46.1M, FDA aligns on Phase 3 design for onvansertib
Cash and investments $46.1M at Q1 end; net cash used $12.3M, runway into Q1 2027.
Cardiff Oncology appoints permanent CEO, new CFO and COO; Muntner gets stock option inducement
Mani Mohindru promoted from interim to President & CEO; base salary $655K, $100K bonus plus 55% discretionary.
Cardiff Oncology finalizes separation agreements with ex-CEO and ex-CFO
Dr. Erlander to receive $635k salary over 12 months, $122k 2025 bonus, and 50% of 2026 target bonus pro-rated.
Phase 2 CRDF-004: ORR 72.2% vs 43.2% combined SoC; PFS HR 0.37 (p<0.05) for 30 mg onvansertib + FOLFIRI/bev in first-line RAS-mutated mCRC.
Cardiff Oncology CEO and CFO step down; onvansertib Phase 2 hits 72.2% ORR in mCRC
CEO Mark Erlander and CFO James Levine stepped down; Mani Mohindru named interim CEO, Brigitte Lindsay promoted to CAO.
Cardiff Oncology Q3 cash $60.6M; Phase 2 trial shows 19% ORR improvement in mCRC
Onvansertib 30mg cohort showed 19% improvement in confirmed ORR vs control in RAS-mutated mCRC Phase 2 trial.
Cardiff Oncology reports 49% confirmed ORR with onvansertib+SoC in Phase 2 mCRC trial; Q2 cash $71M
Confirmed ORR 49% (30mg onvansertib+SoC) vs 30% control in ITT population (N=110); early PFS trend favoring 30mg.
Cardiff Oncology appoints Dr. Roger Sidhu as CMO; to share CRDF-004 data on July 29
Dr. Fairooz Kabbinavar stepped down as CMO effective June 13, 2025; will remain as advisor.
Completed enrollment in Phase 2 CRDF-004 trial of onvansertib + SoC for first-line RAS-mutated mCRC across 41 U.S. sites.
Cardiff Oncology reports Q4 cash $91.7M; 64% ORR for onvansertib plus SOC in RAS-mut mCRC
64% objective response rate (ORR) for 30mg onvansertib + SOC vs 33% control in first-line RAS-mut mCRC trial (CRDF-004).
Cardiff Oncology announces Phase 2 CRDF-004 data: 64% ORR in 30mg onvansertib arm vs 33% control
30mg onvansertib+SoC 64% ORR (7/11) vs 33% (3/9) control; 20mg arm 50% ORR (5/10).
Cardiff Oncology prices $40M underwritten offering of 15.4M shares at $2.60/sh
Gross proceeds ~$40M from 15,384,619 shares at $2.60 per share, before underwriting discounts.
Cardiff Oncology Q3 cash $57.7M; initial CRDF-004 data expected by year-end
Cash, equivalents, and short-term investments of $57.7M as of Sept 30, 2024.
Cardiff Oncology Q2 cash $60.3M; CRDF-004 readout expected 2H 2024
Cash and equivalents $60.3M as of June 30, 2024; runway to Q3 2025.
Cardiff Oncology Q1 2024: $67.2M cash, ONSEMBLE data show 50% ORR in bev naïve mCRC
Cash and equivalents $67.2M as of March 31, 2024; projected runway into Q3 2025.
Bev-naive patients in Phase 1b/2 trial had ORR of 73% vs 19% for bev-exposed; odds ratio 13.64 (p<0.001) and PFS HR 0.21 (p=0.003).
Cardiff Oncology: $75M cash, 50% ORR in ONSEMBLE bev naïve, first patient dosed in CRDF-004 trial
Cash and equivalents of $75M as of Dec 31, 2023; projected runway into Q3 2025.
73% disease control rate in 2L KRAS-mutated mCRC; median overall survival 15 months vs ~8 months historical.
Cardiff Oncology shifts lead mCRC program to first-line; Q3 cash $81.4M
Lead onvansertib program advances to first-line RAS-mutated mCRC; Pfizer Ignite to execute Phase 2 CRDF-004 trial.
Cardiff Oncology reports positive Phase 2 data for onvansertib in pancreatic and lung cancers
mPDAC Phase 2: ORR 19% (1 confirmed PR, 3 pending) vs historical 7.7%; mPFS 5.0 mo vs 3.1 mo.
New lead program in first-line RAS-mutated mCRC; interim topline data expected mid-2024; FDA agreed on endpoints for accelerated approval.
Announces new lead program in first-line RAS-mutated metastatic colorectal cancer with FDA agreement.
Cardiff Oncology Q1 2023: Cash $97M, first patient dosed in ONSEMBLE trial
Cash, cash equivalents & short-term investments of $97M as of March 31, 2023; projected runway into 2025.
Cardiff Oncology reports FY2022 cash of $105.3M; provides clinical updates for onvansertib
Cash, cash equivalents, and short-term investments $105.3M at Dec 31, 2022; projected runway into 2025.
Cash, equivalents, and investments $114M as of Sep 30, 2022; projected runway into 2025.
Phase 1b/2 mCRC data show ORR 35%, mPFS 9.3 mo, median DoR 11.7 mo; historical controls ORR 5-13%, mPFS 4.5-5.7 mo.
Abstract 366P: Onvansertib overcomes irinotecan resistance in RAS-mutated metastatic colorectal cancer in vivo and in patients (EAP).
Cash, equivalents, and short-term investments of ~$122M as of June 30, 2022; net cash used in Q2 2022 was $6.7M, up from $4.3M in Q2 2021.
Cardiff Oncology Q1 2022: cash $129.4M; mCRC trial shows improved ORR/PFS vs historical controls
Cash, equivalents & short-term investments ~$129.4M as of Mar 31, 2022; net cash used in ops $10.2M.
CMO Katherine Ruffner leaving April 22, 2022; will provide transitional support.
Arm C (12 mg/m2 onvansertib days 1-14) achieved 75% radiographic stable disease at 12 weeks vs 53% in Arm A.
Cardiff Oncology reports Q4/FY2021 results; mCRC trial shows 34% ORR; Pfizer invests $15M
Onvansertib+FOLFIRI/bevacizumab in KRAS-mutated mCRC: 34% (12/35) ORR at RP2D; mPFS 9.4 months vs ~4.5-5.7 months historical control.
On June 13, 2025, Dr. Fairooz Kabbinavar and Cardiff Oncology, Inc. (the “Company”) agreed that he would be stepping down from his position as Chief Medical Officer.
On June 17, 2025, the Company announced that it has appointed Dr. Roger Sidhu as its new Chief Medical Officer and entered into an employment agreement with Dr. Sidhu on June 16, 2025 (the “Sidhu Employment Agreement”).
On January 30, 2023, Cardiff Oncology, Inc. (the “Company”) appointed Dr. Fairooz Kabbinavar as Chief Medical Officer of the Company
Sandra L. Silberman, M.D., Ph.D., who previously acted as a chief medical advisor to Cardiff Oncology from June 2017 to July 2021, has agreed to serve as the Company’s senior medical advisor and oversee its clinical trials and clinical operations team on an interim basis.
On April 12, 2022, Cardiff Oncology, Inc. (the “Company”) announced that Katherine Ruffner, M.D., the Company’s Chief Medical Officer, will be leaving the Company on April 22, 2022, to pursue a new opportunity.
On July 6, 2021, Cardiff Oncology, Inc. (the “Company”) appointed Dr. Katherine Ruffner as Chief Medical Officer of the Company.
In addition, on July 12, 2021, the Company entered into an employment agreement with James Levine (the “Levine Employment Agreement”) pursuant to which Mr. Levine will be the Chief Financial Officer of the Company.
Max materiality 0.90 · Median 0.60 · Most common event other_material